Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, milestone payments, and complex royalty schedules make Cytokinetics filings notoriously dense. Whether you’re dissecting how a cardiac myosin activator advances through Phase III or estimating the company’s cash runway, combing through hundreds of pages can stall decisive action.
Stock Titan turns that obstacle into clarity. Our AI instantly delivers Cytokinetics SEC filings explained simply, mapping each section of the Cytokinetics annual report 10-K simplified to the questions investors actually ask. Need the latest Cytokinetics quarterly earnings report 10-Q filing? We surface R&D spend and partnership revenue in seconds. Looking for Cytokinetics insider trading Form 4 transactions or Cytokinetics Form 4 insider transactions real-time? Alerts arrive the moment EDGAR posts. You can even see trial-related surprises through our summaries of Cytokinetics 8-K material events explained. Key use cases include:
- Tracking Cytokinetics executive stock transactions Form 4 before clinical read-outs
- Comparing pipeline costs across quarters with our Cytokinetics earnings report filing analysis
- Reviewing Cytokinetics proxy statement executive compensation to align leadership incentives with drug-approval timelines
- Understanding Cytokinetics SEC documents with AI-generated plain-English notes
Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A and more—is captured in real time, then distilled by our expert models. Spend less time scrolling and more time deciding when trial milestones or insider moves signal opportunity.
Insider transaction summary for CYTK: The Form 4 shows Robert I. Blum, President & CEO and a director of Cytokinetics Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 08/15/2025 at a price of $38.42 per share. After the reported sale, Mr. Blum is recorded as directly owning 383,108 shares. The filing also discloses indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
The Form 4 was filed by one reporting person and indicates the transaction may have been made pursuant to a written plan under Rule 10b5-1. The filing is signed by an attorney-in-fact for Mr. Blum on 08/15/2025.
Cytokinetics (CYTK) Q2-25 10-Q highlights: Revenue jumped to $66.8 m (Q2-24: $0.3 m) and $68.3 m for H1, driven by the Bayer Japan license (one-time $52.4 m recognition) and two €5 m milestones. Collaboration revenue remains modest. Operating loss narrowed to $111.5 m (-14% YoY), but six-month operating loss widened to $335.5 m. Net loss was $134.4 m for the quarter (-$1.12/sh) and $295.7 m YTD.
Balance sheet & liquidity: Cash, cash equivalents and investments total $1.0 bn, down from $1.2 bn at FY-24. Quarterly cash burn from operations was $259.9 m. Total liabilities rose to $1.59 bn (incl. $554 m convertible notes and $489 m revenue-participation liabilities) producing a stockholders’ deficit of $368.7 m. Additional $75 m was drawn on Royalty Pharma Tranche 4 in April; Tranche 5 ($100 m) remains available through Nov-25.
Pipeline/regulatory: NDA for aficamten in obstructive HCM accepted; PDUFA target date 26 Dec 2025. Phase 3 programs in non-obstructive HCM and pediatric HCM progressing. Omecamtiv mecarbil Greater China license terminated; rights reverted to CYTK. Cash runway expected to cover at least 12 months; management anticipates continued losses until commercial launch.
EVP R&D Dr. Fady I. Malik reported one option exercise and a matching open-market sale on 22 Jul 2025. He exercised 2,000 non-qualified options at $10.60, receiving 2,000 CYTK shares (Code M), then sold the same 2,000 shares at $37.47 (Code S). Net share count declined slightly from 142,610 to 140,610 shares, all held directly. Malik still holds 13,105 unexercised options with a $10.60 strike expiring 28 Feb 2027.
The trade represents roughly 1.4% of his direct equity position and appears to be a routine liquidity event following option exercise rather than a wholesale reduction. No other executives are involved and there are no disclosures affecting company fundamentals.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
